Drugs / HRS-7053
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05983146 | Sep 2023 → May 2025 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-7053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05983146 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05983146 ↗ |